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Background
The risk of non Hodgkin's lymphoma (NHL) is 150–250
times higher among HIV infected patients. In developed
countries with open access to highly active antiretroviral
therapy (HAART), the prognosis of these patients appears
to be impacted positively, and survival in some groups
can be similar to non-HIV infected patients. Recent data
has shown improved survival among NHL-HIV+ patients
receiving standard chemotherapy (QT) HAART, with
acceptable range of toxicity.
Objective
To analyze the median survival of patients with AIDS with
and without NHL and NHL-HIV negative patients.
Materials and methods
We etrospectively reviewed all medical records of patients
with NHL-HIV+ seen from January 1990 to December
2005 at the Instituto Nacional de Cancerologia in Mexico
City, Mexico. We used as control groups patients with
AIDS (defining-event non-lymphoma related), and
patients with NHL treated as well at our institution, diag-
nosis made ± 3 years, with same gender and age ± 5 years.
We recorded clinical, laboratory and pathology data; sur-
vival or follow-up time was calculated from date of diag-
nosis to death or to the date when the patient was last
seen.
Results
Sixty-nine patients were diagnosed with NHL-HIV. AIDS
control patients (n = 93) were divided into no-HAART
and HAART; and NHL/HIV negative control patients (n =
90) were divided into incomplete (<3 cycles or <100% of
total dose), and complete chemotherapy (Table 1)
Conclusion
Survival in patients with AIDS is better than in NHL/HIV+
and NHL/HIV-. The use of HAART has significantly
improved sthe prognosis. Mean survival with the use of a
complete chemotherapy regime is similar in patients with
NHL and in patients with NHL/HIV+.
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Table 1: Mean survival for NHL/HIV+, NHL/HIV negative and AIDS groups
NHL/HIV+ (n = 69) AIDS (n = 93) p
No-HAART (months ± SD) 5.01 ± 7.7 (n = 27) 25.9 ± 25.12 (n = 40) 0.001
HAART (months ± SD) 15.75 ± 19.4 (n = 42) 50 ± 37.9 (n = 53) <0.0001
Total (months ± SD) 11.5 ± 16.7 39.7 ± 35 <0.0001
NHL/HIV NHL (n = 90)
Incomplete chemotherapy (months ± SD) 4.32 ± 5.5 (n = 40) 1.84 ± 1.66 (n = 22) 0.04
Complete chemotherapy(months ± SD) 21.3 ± 20.26 (n = 29) 29.07 ± 36.27 (n = 68) 0.286
Total(months ± SD) 11.5 ± 16.7 22.41 ± 33.61 0.01